The CoronaVirus Disease 19 (COVID-19) pandemic is a threat of particular concern for people affected by chronic immune-mediated diseases, such as multiple sclerosis (MS), who are often treated with immunomodulatory and immunosuppressive drugs, which may increase the risk of infections in general. At the beginning of the COVID-19 pandemic, empirical guidelines on how to manage treatments for immune-mediated diseases, including MS, were released. Subsequently, the first clinical pictures and data sets have been published, describing the outcomes of COVID-19 in patients with MS treated with immunomodulatory and immunosuppressive drugs. Here we will review available information on how infections by human coronaviruses affect the immune system in untreated subjects and in patients affected by MS treated with drugs which modulate the immune system.

中文翻译：

---

COVID-19 在接受疾病缓解治疗的多发性硬化症患者中

冠状病毒病 19 (COVID-19) 大流行是受慢性免疫介导疾病（如多发性硬化症 (MS)）影响的人特别关注的威胁，他们经常接受免疫调节和免疫抑制药物治疗，这可能会增加患一般感染。在 COVID-19 大流行之初，发布了有关如何管理免疫介导疾病（包括 MS）治疗的经验指南。随后，发布了第一批临床图片和数据集，描述了 COVID-19 在接受免疫调节和免疫抑制药物治疗的 MS 患者中的结果。在这里，我们将回顾有关人类冠状病毒感染如何影响未经治疗的受试者和用调节免疫系统的药物治疗的 MS 患者的免疫系统的可用信息。